Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)

院前抗纤溶药物治疗创伤性凝血功能障碍和出血（PATCH 研究）

• 批准号: nhmrc : GNT1044894
• 负责人: A/Pr Huyen Tran
• 金额: $ 166.82万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/pre-hospital-antifibrinolytics-patch-study/1344451
• 关键词: Pre; hospital; Antifibrinolytics; Traumatic; Coagulopathy

About 2500 Australians die annually from severe injuries. Bleeding is exacerbated by early-onset clotting defects, which are associated with high mortality. The antifibrinolytic agent tranexamic acid has been shown to reduce mortality due to bleeding when given in hospital in less developed trauma systems, but its usefulness as a pre-emptive strike at the scene of injury in developed systems is unknown. Building on our prehospital clinical trials expertise, we will conduct a trial to assess its effect on 6-month death and disability.

每年约有2500名澳大利亚人死于严重伤害。早发性凝血缺陷会加剧出血，这与高死亡率相关。抗纤维蛋白溶解剂氨甲环酸已被证明可以降低因出血而导致的死亡率，当在医院给欠发达的创伤系统，但其作为一个先发制人的打击在发达系统的损伤现场的有用性是未知的。基于我们的院前临床试验专业知识，我们将进行一项试验，以评估其对6个月死亡和残疾的影响。